2022
DOI: 10.1016/s1473-3099(22)00574-6
|View full text |Cite
|
Sign up to set email alerts
|

Prevention of monkeypox with vaccines: a rapid review

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
165
0
3

Year Published

2022
2022
2024
2024

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 163 publications
(170 citation statements)
references
References 76 publications
2
165
0
3
Order By: Relevance
“…The monkeypox outbreak arrived in a different context than that of COVID-19, since approved vaccines against Smallpox can confer protection against Monkeypox in both pre-exposure and post-exposure contexts [ 36 ]. Moreover, tecovirimat, an antiviral drug, which might present a potential use to treat some cases of Monkeypox, is showing preliminary positive results in placebo-controlled pharmacokinetic and safety trial [ 37 ] and observational studies [ 38 , 39 ].…”
Section: Discussionmentioning
confidence: 99%
“…The monkeypox outbreak arrived in a different context than that of COVID-19, since approved vaccines against Smallpox can confer protection against Monkeypox in both pre-exposure and post-exposure contexts [ 36 ]. Moreover, tecovirimat, an antiviral drug, which might present a potential use to treat some cases of Monkeypox, is showing preliminary positive results in placebo-controlled pharmacokinetic and safety trial [ 37 ] and observational studies [ 38 , 39 ].…”
Section: Discussionmentioning
confidence: 99%
“…Overall, 26,980 (82.0%) respondents reported they would accept MPX vaccination (Table 1), with 20,266 (61.6%) and 6,714 (20.4%) who would respectively surely or probably accept it (Supplementary Material S3; sample description reporting all vaccine acceptance categories). A total of 2,890 (8.8%) were hesitant and 2,686 (8.2%) would likely (1,236, 3.8%) or surely (1,450,4.4%) refuse to get vaccinated.…”
Section: Monkeypox Vaccination Acceptancementioning
confidence: 99%
“…Since March 2022, a multi-country outbreak of the monkeypox (MPX) virus has been predominantly affecting gay, bisexual and other men who have sex with men (MSM) in non-endemic countries. Data suggest that immunisation against smallpox confers a high degree of protection and immunity against MPX virus [ 1 ]. Nonetheless, vaccine hesitancy may pose an important barrier to control efforts.…”
mentioning
confidence: 99%
“…JYNNEOS, unlike ACAM2000™, is not contraindicated for use in people with immunodeficiencies such as atopic dermatitis and acquired immunodeficiency syndrome (AIDS) [117] . LC16m8, another third-generation vaccine, is derived from the Lister strain of vaccinia virus and produced in cell culture using rabbit kidney cells [118] . Japanese regulators fully licensed the vaccine in 1980, and it is currently manufactured by Kaketsuken (Kumamoto, Japan).…”
Section: Prophylaxis and Treatmentmentioning
confidence: 99%